During the past decade, Orszagos Onkologiai Intezet conducted 95 clinical trials. In the 10-year time frame, 95 clinical trials started and 42 clinical trials were completed, i.e. on average, 44.2% percent of trials that started reached the finish line to date. In the past 5 years, 44 clinical trials started and 26 clinical trials were completed. i.e. 59.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Orszagos Onkologiai Intezet" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 13 trials sponsored, "Pfizer" with 12 trials sponsored, "ETOP IBCSG Partners Foundation" with 10 trials sponsored and "National Institute of Oncology, Hungary" with 10 trials sponsored. Other sponsors include 93 different institutions and companies that sponsored additional 75 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Orszagos Onkologiai Intezet" #1 collaborator was "Merck Sharp & Dohme LLC" with 5 trials as a collaborator, "Breast International Group" with 4 trials as a collaborator, "NCIC Clinical Trials Group" with 4 trials as a collaborator, "National Cancer Institute (NCI)" with 4 trials as a collaborator and "ADIR, a Servier Group company" with 3 trials as a collaborator. Other collaborators include 58 different institutions and companies that were collaborators in the rest 54 trials.

According to Clinical.Site data, the most researched conditions in "Orszagos Onkologiai Intezet" are "Breast Cancer" (21 trials), "Colorectal Cancer" (6 trials), "Breast Neoplasms" (4 trials), "Chronic Lymphocytic Leukemia" (4 trials) and "Melanoma" (4 trials). Many other conditions were trialed in "Orszagos Onkologiai Intezet" in a lesser frequency.

Most popular intervention types in "Orszagos Onkologiai Intezet" are "Drug" (139 trials), "Biological" (18 trials), "Procedure" (14 trials), "Radiation" (7 trials) and "Device" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Gemcitabine" (10 trials), "Rituximab" (10 trials), "Docetaxel" (8 trials) and "Paclitaxel" (8 trials). Other intervention names were less common.

The vast majority of trials in "Orszagos Onkologiai Intezet" are 116 trials for "All" genders, 29 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are NaN active trials in "Orszagos Onkologiai Intezet". undefined are not yet recruiting, 31 are recruiting, 29 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 70 completed trials in Orszagos Onkologiai Intezet, undefined suspended trials, and 18 terminated clinical trials to date.

Out of the total trials that were conducted in Orszagos Onkologiai Intezet, 15 "Phase 1" clinical trials were conducted, 40 "Phase 2" clinical trials and 101 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".

Orszagos Onkologiai Intezet has several departments that took part in Clinical trials: "Orszagos Onkologiai Intezet "B" Belgyogyaszati osztaly" - 22 trials, "Országos Onkológiai Intézet, C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály" - 8 trials, "Orszagos Onkologiai Intezet - Nogyogyaszati Osztaly" - 4 trials, "Orszagos Onkologiai Intezet; Borgyogyaszati Osztaly" - 4 trials, "Orszagos Onkologiai Intezet Sugarterapias Osztaly" - 3 trials, "Orszagos Onkologiai Intezet, Gyogyszertar" - 2 trials